Antibodies against LAG-3 have been tested in repeated clinical trials, particularly in metastatic breast and pancreatic cancers; blocking LAG-3 alone had little effect on TEX function during chronic LCMV infection, however, blocking LAG-3 in the combination of the IR of the PD-1 can forcefully regain T-cell cytotoxicity. This evidence concerns the gene LAG3 and familial pancreatic carcinoma.